Enerev5 Metals Updates Private Placement

Toronto, Ontario--(Newsfile Corp. - June 10, 2022) - Enerev5 Metals Inc. (TSXV: ENEV) (OTCQB: ENEVF)(the "Company") announces that the TSX Venture Exchange has granted an extension of up to 30 days for completion of the balance of the Company's brokered private placement through IBK Capital Corp. of up to $500,000 of units first announced on March 8, 2022. Each unit is priced at $0.05 and consists of one common share and one common share purchase warrant. Each common share purchase warrant entitles the holder to acquire one additional common share at a price of $0.10 for a period of 24 months from the closing date. To date, the Company has completed three tranches of the private placement raising gross proceeds of $215,500 from the sale of 4,310,000 units.

About Cobalt Blockchain Inc.

Enerev5 Metals Inc. (TSXV: ENEV) (OTCQB: ENEVF) is a Canadian resource company focusing on exploration and development potential, related to energy metals such as cobalt, copper and other strategic battery minerals, as well as other net zero related assets. ENEV is committed to exploration and development programs contributing towards net zero carbon and a sustainable energy future.

For more information on the Company, investors should review the Company's filings at www.sedar.com.

For additional information, please contact:

Peter Copetti
Executive Chairman and CEO
Enerev5 Metals Inc.
Telephone: +1-416-519-4009
Email: [email protected]
Website: www.enerev5.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FORDISSEMINATION IN THE U.S.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/127260

You May Also Be Interested In

• Stellantis and Nissan reportedly in talks for Marelli bankruptcy assets
• Federal Court Hands Bunker Hill Mining Significant Summary Judgment Victory Over Crescent
• Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy